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ABSTRACT
Positioning of release factor eRF1 toward adenines
and the ribose-phosphate backbone of the UAAA
stop signal in the ribosomal decoding site was
studied using messenger RNA (mRNA) analogs con-
taining stop signal UAA/UAAA and a photoactivat-
able cross-linker at definite locations. The human
eRF1 peptides cross-linked to these analogs were
identified. Cross-linkers on the adenines at the 2nd,
3rd or 4th position modified eRF1 near the con-
served YxCxxxF loop (positions 125–131 in the N
domain), but cross-linker at the 4th position mainly
modified the tripeptide 26-AAR-28. This tripeptide
cross-linked also with derivatized 30-phosphate of
UAA, while the same cross-linker at the 30-phos-
phate of UAAA modified both the 26–28 and 67–73
fragments. A comparison of the results with those
obtained earlier with mRNA analogs bearing a
similar cross-linker at the guanines indicates that
positioning of eRF1 toward adenines and guanines
of stop signals in the 80S termination complex is
different. Molecular modeling of eRF1 in the 80S ter-
mination complex showed that eRF1 fragments
neighboring guanines and adenines of stop sig-
nals are compatible with different N domain con-
formations of eRF1. These conformations vary by
positioning of stop signal purines toward the univer-
sally conserved dipeptide 31-GT-32, which neigh-
bors guanines but is oriented more distantly from
adenines.
INTRODUCTION
Elongation of the polypeptide chain of a protein that
is synthesized on the ribosome terminates when one of
three nonsense, or stop codons of the messenger RNA
(mRNA), UAA, UGA or UAG, appears at the ribosomal
A-site instead of sense codons encoding for amino acids.
Thus, termination of polypeptide synthesis is one of the
key steps of translation: it ensures formation of the
normally sized proteins. Stop codons are decoded at the
ribosome by polypeptide chain release factors class 1
(RF1/RF2 in bacteria or eRF1 in eukaryotes) that are
responsible for the recognition of the A-site-bound stop
codons and triggering hydrolysis of the complex ester
bond between the peptidyl moiety and the 30-terminal
ribose of the P-site-bound peptidyl-transfer RNA
(tRNA) at the ribosomal peptidyl transferase center
(1–3). The process also involves termination factor class
2 (RF3 in bacteria or eRF3 in eukaryotes), eRF3 is the
ribosome- and eRF1-dependent GTPase (4). RF3 is essen-
tial for dissociation of RF1/RF2 from the ribosome after
termination (5) while eRF3 ensures rapid and efﬁcient hy-
drolysis of peptidyl-tRNA (6). Moreover, eRF3 stimulates
release activity of eRF1 (4,6,7), with which it can form a
stable complex (8–11). Although steps of translation ter-
mination in bacteria and eukaryotes share considerable
similarity, bacterial and eukaryotic class 1 RFs do not
possess any obvious sequence homology (3,12,13) and
there are numerous indications that molecular mechan-
isms of termination on 70S and 80S ribosomes are differ-
ent (14). Structural aspects of the interaction of bacterial
RF1/RF2 with the ribosome and mechanisms of stop
codon recognition by these factors are well studied, in
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lography and cryo-electron microscopy (15–17). The
crystal structures of eRF1 in solution (18) as well as the
ribosome-free complexes of eRF1 with eRF3 (19) have
been solved. However, structural information on the
positioning of eRF1 in the 80S termination complexes is
limited since these complexes have not yet been
studied by either cryo-electron microscopy or X-ray crys-
tallography that has only recently been adapted to
decipher the structure of ribosomes of lower
eukaryotes (20,21).
The conventional point of view is that eRF1 has a
tRNA-mimic structure, in which the universal GGQ
motif located on the tip of the M domain of eRF1 and
common to all class-1 RFs is equivalent to the acceptor
end of tRNAs, while the conserved NIKS motif (positions
61–64 in human eRF1) recognizing the ﬁrst uridine of the
stop codon corresponds to the anticodon loop of tRNAs
(3). In the three-dimensional structure of eRF1, the stop
codon recognition site (‘anticodon’) is discontinuous and,
besides the NIKS motif, includes the highly conserved
YxCxxxF motif (positions 125–131) involved in the recog-
nition of purines (19,22,23). Apparently, eRF1 cannot be
positioned in the ribosomal A-site in the form known from
X-ray crystallographic studies (18) since the distance
between the GGQ and NIKS motifs in eRF1 is about
100A ˚ that is much larger than the distance between the
acceptor end and the anticodon loop in a tRNA (typically,
75–80A ˚ ). This implies that eRF1 can be adopted at the
ribosomal A-site only when it undergoes major conform-
ational rearrangements. Such rearrangements have been
observed in the X-ray crystallographic studies of eRF1
complexed with eRF3 (19) and modeled (24).
It is clear that information on the positioning of eRF1
with respect to the components of 80S translation termin-
ation complexes is essential to understand molecular
mechanisms of translation termination in eukaryotes.
Data on the eukaryotic stop codon recognition site have
mainly been obtained by investigating the effects of mu-
tations in designed regions of eRF1 on recognition of par-
ticular stop codons and do not provide direct information
on positioning of eRF1 with respect to the A-site-bound
stop codon in the 80S termination complex (22,23,25–30).
This information has been obtained partially from X-ray
studies of the eRF1 eRF3 complex containing a bound
ATP molecule that mimicked a nucleotide of stop codon
according to authors’ suggestion (19), and from results on
site-directed cross-linking of the A-site-bound stop codon
to eRF1 in the 80S ribosomal termination complexes
(24,31). It is evident that the data for ribosome-free
eRF1 eRF3 ATP complexes (19) cannot adequately
reﬂect positioning of a stop codon in the 80S termination
complex in contrast to cross-linking data. The use of a set
of mRNA analogs with perﬂuorophenyl azide-derivatized
guanines made it possible to identify the conserved N
domain YxCxxxF and the GTx motifs as neighbors of
the guanine of the A-site-bound UGA and UAG stop
codons (24). However, positioning of eRF1 with respect
to the adenines of stop codons in the 80S termination
complexes remained to be studied. For this reason, in
the current study we examined positioning of the
adenines of the UAAA terminating tetraplet with respect
to eRF1 in the 80S termination complexes using mRNA
analogs bearing UAA or UAAA at the 30-end and the
perﬂuorophenyl azide cross-linker at the C8 of the adeno-
sine or at the 30-terminal phosphate. Identiﬁcation of the
peptides cross-linked to nucleotides of the stop signal and
comparison of the results obtained with data on molecular
modeling of eRF1 ﬁtted to the A-site adjacent to the
P-site-bound tRNA makes it possible to conclude that
eRF1 adopts different conformations of its N domain to
recognize adenines and guanines of stop codons.
MATERIALS AND METHODS
tRNA
Phe (1300pmol/A260 unit) was a kind gift from
Dr. V. Katunin (Konstantinov’s St. Petersburg Institute
of Nuclear Physics, Gatchina, Russia). Isolation of the
40S and 60S ribosomal subunits from unfrozen human
placenta and their association in 80S ribosomes were per-
formed as described (32). The activity of the ribosomes
in the poly(U)-directed binding of [
14C]Phe-tRNA
Phe
was  70% (extent of binding was about 1.4mol of Phe-
tRNA
Phe per mole of the 80S ribosomes at saturating
concentration of Phe-tRNA
Phe).
mRNA analogs
Synthesis and puriﬁcation of derivatives of oligoribonu-
cleotides bearing an 4-azido-2,3,5,6-tetraﬂuorobenzoyl
group attached via speciﬁc spacers to either the 30-terminal
phosphate or the C8 of the adenine were carried out
as described in refs. 33 and 34, respectively. Before use
in the cross-linking experiments, the derivatives were
50-
32P-labeled and puriﬁed (35).
eRF1
DNA constructions for the preparation of recombinant
human eRF1 and its mutants with a C-terminal His-tag
were described (23,31,36). The eRF1 proteins were
expressed in Escherichia coli and puriﬁed by afﬁnity chro-
matography as described (37). The eRF1 activity was
measured in vitro as described (38,39).
Ribosomal complexes and cross-linking procedures
Complexes of 80S ribosomes (5.0 10
 7M) with tRNA
Phe
(5 10
 6M) and mRNA analogs (3.5 10
 6M) were
obtained by incubating these components for 40min in
buffer A [20mM HEPES-KOH, pH 7.5, 100mM
NH4Cl, 4mM MgCl2, 0.2mM ethylenediaminetetraacetic
acid (EDTA), 0.6mM spermidine and 0.8mM spermine]
at room temperature. The reaction mixtures for cross-
linking experiments contained 15pmol of 80S ribosomes.
Then wild-type (wt)-eRF1 or mutant eRF1 was added,
where speciﬁed, in a 7-fold molar excess each over the
80S ribosomes and the reaction mixtures were further
incubated for 40min at room temperature. To obtain
cross-links between mRNA analogs and eRF1, complexes
were ultraviolet (UV)-irradiated as described (40).
Reactions were stopped with 1/30 v/v of 5% 2-mercapto-
ethanol and the ribosomal complexes were puriﬁed by
Nucleic Acids Research, 2011,Vol.39, No. 16 7135centrifugation in a sucrose gradient (15–30%) containing
buffer A with 1mM 2-mercaptoethanol as described (33).
eRF1 mapping
Isolation of eRF1 (wild-type or mutant) cross-linked to a
labeled mRNA analog in the termination complex, its
CNBr-induced cleavage and separation of the resulting
fragments were carried out as described (24). Selective
cleavage of the labeled eRF1 fragments obtained as a
result of CNBr-induced digestion of cross-linked eRF1
with the endoproteases GluC, ArgC (Roche), pepsin
(Sigma-Aldrich) or with hydroxylamine and separation of
the resulting fragments by 16.5% Tris–tricine sodium
dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE) were performed according to ref. 24; the
gels were dried and radioautographed. Hydrolysis of
cross-linked eRF1 oligopeptides corresponding to radio-
active bands excised from the dried gels with endoprotease
AspN (Roche) was carried out in 100mlo f1 0 m M
Tris–HCl buffer, pH 7.5, containing 0.001mg/ml of the
enzyme by incubating of mixture overnight at 37 C with
subsequent analysis by Tris–tricine SDS–PAGE as
described.
RESULTS
mRNA analogs
The mRNA analogs contained the Phe codon UUC
followed either by the UAA(p) triplet or the UAAA(p)
tetraplet and carried a perﬂuorophenyl azide group
attached via a spacer to the C8 atom of the adenine or
to the 30-terminal phosphate (Figure 1A). mRNA analogs
containing sense codons (pUUCUA*CAAA, pUUCUC
A*AAA, and pUUCUCAp*) were used in control experi-
ments. The position of the modiﬁed nucleotide varied
from the second to the fourth position in the termination
tetraplet. The UUC codon of the mRNA analogs was
targeted to the ribosomal P site by tRNA
Phe so that the
adjacent modiﬁed stop codon was directed to the A site
(Figure 1B). This complex is referred as a ‘phased’
ribosome.
Cross-linking of mRNA analogs to the components of the
ribosomal complexes
Complexes of 80S ribosomes with mRNA analogs and
tRNA
Phe obtained in the presence of eRF1 were irradiated
and then puriﬁed to remove eRF1 that could be cross-
linked to mRNA analogs outside of the ribosome (24).
The results of cross-linking of mRNA analogs (Figure 1A)
to ribosomal proteins and eRF1 presented in Figure 2 are
similar to those obtained recently with the use of similar
mRNA analogs with derivatized guanines (24). In particu-
lar, the addition of tRNA
Phe to mixtures of ribosomes
with mRNA analogs results in signiﬁcant enhancement
of cross-linking to some ribosomal proteins (Figure 2,
compare lanes 1 with other lanes). Protein bands in the
upper and middle parts of the gels correspond to cross-
linked proteins S2/S3 and S15, respectively. This assign-
ment is based on our earlier studies where these proteins
have been found to cross-link to mRNA analogs whose
perluorophenyl azide-modiﬁed nucleotides were placed on
the 80S ribosome in positions+4 to+7 with respect to the
ﬁrst nucleotide of the P-site-bound codon (40,41). Strong
tRNA-dependent cross-linking to protein S15 has been
shown to be characteristic for the modiﬁed nucleotides
in mRNA positions from +4 to +7; in Figure 2, the re-
spective bands are seen in lanes 2 and 3 with phased ribo-
somes but not in lanes 1 corresponding to complexes
obtained without tRNA. In contrast, cross-linking to
proteins S2/S3 slightly depends on the presence of tRNA
(40,41); in Figure 2, the respective bands are seen in all
lanes.
The addition of eRF1 to the phased ribosomes with
subsequent irradiation causes appearance of a new radio-
active band in the upper part of the gels (Figure 2, lanes 3)
whose mobility corresponds to that of eRF1 (Figure 2,
lanes 4). This cross-linking to eRF1 is speciﬁc for the
mRNA analogs containing stop codon UAA since
mRNA analogs bearing UAC or UCA sense codon with
modiﬁed adenosine or 30-terminal phosphate cross-link to
eRF1 negligibly (Figure 2, lanes 5). The yield of the cross-
link eRF1-mRNA analog depends both on the position of
modiﬁed nucleotide and on the site of the cross-linker in it.
The lowest yield is observed with mRNAs I and II bearing
a modiﬁed A in the second and third stop codon positions,
respectively (Figure 2).
Figure 1. mRNA analogs and ribosomal complexes. (A) mRNA analogs used here. (B) 80S ribosome complexed with an mRNA analog, tRNA and
polypeptide chain release factor eRF1. The distance separating the modiﬁed adenine base (or the 30-phosphate) and the ﬁrst nitrogen of the
azidogroup is  11A ˚ .
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protein by CNBr-induced cleavage
The strategy used for the initial mapping of the cross-
linking sites on the eRF1 was based on the speciﬁc
CNBr-induced complete cleavage of eRF1 after methio-
nine residues with subsequent SDS–PAGE analysis of
the resulting fragments (24). The data presented in
Figure 3 show that all lanes share a band marked ‘a’ cor-
responding to the products whose masses after sub-
tracting the masses of the cross-linked mRNA analogs
(ranging from 2.2 to 3.2kDa) were  16kDa (Figure 3A).
This band can be unambiguously assigned to the cross-
linked 52–195 fragment of eRF1 (Figure 3B). With
mRNAs III, IV and V, one can observe the faster
migrating band b together with band a (Figure 3A, lanes
3–5), and the relative intensities of these bands depend
on the site of the cross-linker in the mRNA analog.
Thus, band b is much stronger than band a in the case
of mRNA III (Figure 3A, lane 3), while with mRNA V
band a is stronger (Figure 3A, lane 5). In experiments
with mRNA IV, practically only band b is observed
(Figure 3A, lane 4).
Mapping of the cross-linking sites corresponding to
band ‘a’
To precisely identify the positions of the cross-links in
the 52–195 fragment, the strategy applied earlier for
guanosine-derivatized mRNA analogs was used (24). To
examine cross-linking of mRNAs I–III in the region of the
YxCxxxF motif, which was one of the targets
for cross-linking in the above-mentioned study, eRF1
mutants with double amino acid substitutions were used.
One out of two substitutions eliminated the CNBr
cleavage site in the wt-eRF1 that borders the 51–195
fragment (M195L or M51A), and another substitution
inserted a new artiﬁcial site for CNBr cleavage absent in
the wt-eRF1 near or within the YxCxxxF motif (K109M,
I120M, L124M, L126M or H132M). The results of the
SDS–PAGE analysis of cross-linked products obtained
with the eRF1 mutants are presented in Figure 4. With
the mRNA analogs I–III, the labeled products corres-
ponding to the upper bands migrate more slowly with
the mutant K109M+M195L than with I120M+M195L
(Figure 4A, left panel, lanes 2 and 3). This is possible only
if the cross-linking sites are in the fragments 110–241 and
121–241, respectively (Figure 4B, lanes 2 and 3), restrict-
ing location of the cross-links within positions 121–195
with all mRNA analogs. The data obtained with the re-
maining eRF1 mutants are presented in Figure 4A (right
panel). A comparison of the mobilities of the products
corresponding to the upper bands (Figure 4A, lanes
4–6 with mRNA I) with the cleavage map presented in
Figure 4B shows that with mRNA I cross-linked frag-
ments can only be aa 125–195, 127–195 and 35–132; there-
fore, the cross-link is in positions 127–132. Similarly,
the data obtained with mRNA III clearly imply that the
cross-linked fragments are aa 35–124, 35–126 and 35–132
(compare lanes 4, 5 and 6 with mRNA III in Figure 4A
and B). Taking into account that all mRNAs I–III
cross-links corresponding to the upper bands are in pos-
itions 121–195, one can conclude that the site of mRNA
III cross-linking lies within positions 121–124. Finally,
with mRNA II two cross-linking sites exist, in positions
121–124 and 125–132 (Figure 4A and B, lanes 4–6).
As for mRNA IV, the mapping has not been carried out
since with the above-mentioned mutants yield of cross-
linking corresponding to band a is too low (Figure 3,
lane 4). In the experiments with the mutants and mRNA
V, the position of band a is the same as with the wt-eRF1
(data not shown). Thus, in this case the cross-linking site is
outside from the YxCxxxF region. To map the cross-link
with mRNA V, a set of eRF1 mutants carrying single
amino acid substitutions for Met in another putative
region of the 52–195 fragment was used, namely, the
region of the NIKS motif (fragment 61–64). These
mutants were previously used to identify the eRF1
fragment cross-linked to the ﬁrst nucleotide of a stop
codon (24,31). The results presented in Figure 5 clearly
show that with mutant V66M the cross-linked fragment
is slightly shorter than with wt-eRF1, while with mutant
G73M it is drastically shorter (lanes 2 and 3). These data
imply that the respective cross-linked fragments are aa 67–
195 and 52–73, respectively (Figure 5B, compare lanes 2
Figure 2. Electrophoretic analyses of irradiated ribosomal complexes.
Autoradiogram of SDS–PAGE. Upper parts of the gels with rRNA
bands are not shown. Complexes are numbered according to the lane
numbers (indicated above the autoradiograms). 80S mRNA (1), 80S 
mRNA tRNA
Phe (2), 80S mRNA tRNA
Phe eRF1 (3). Lane 4, stained
electrophoregrams of eRF1. Lane 5, complexes 80S mRNA (sense) 
tRNA
Phe obtained in the presence of eRF1 with the use of mRNA
analogs pUUCUA*CAAA, pUUCUCA*AAA and pUUCUCAp*
instead of mRNAs I, II and IV, respectively. Bands corresponding to
cross-linked eRF1 and ribosomal proteins (marked with asterisks) are
indicated by arrows.
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positions 67–73.
Mapping of the cross-linking sites corresponding to
bands ‘b’
The electrophoretic mobilities of products corresponding
to bands b with mRNAs III–V are somewhat different,
but these differences evidently relate to the masses of the
mRNA analogs cross-linked to oligopeptides rather than
with masses of the oligopeptides subjected to the cross-
linking. The most slowly migrating product is observed
with mRNA III (a nonamer), the fastest is obtained with
mRNA IV (a hexamer) and the oligopeptide cross-linked
to mRNA V (a heptamer) has an intermediate mobility.
The apparent masses of the oligopeptides after subtracting
the masses of the cross-linked mRNA analogs are in the
range of 4–5kDa. However, the molecular mass of the
cross-linked product migrating as band b could be not
exactly the same as expected from its electrophoretic
mobility due to inﬂuence of the cross-linked oligonucleo-
tide moiety on the mobility of the modiﬁed oligopeptide in
the gel. The shorter the oligopeptide is, the more effect of
the cross-linked oligonucleotide is expected. Therefore,
bands b observed with mRNAs III–V can correspond to
any of four candidate fragments 2–34, 196–241, 330–372
and 373–422 whose molecular masses are rather close to
the expected range of 4–5kDa (Figure 3B). Cross-linking
within the fragment 196–241 is excluded based on the
results obtained with mutants K109M+M195L and
I120M+M195L (see above) since CNBr-induced
cleavage of these mutants cross-linked to mRNA III
produced the same bands b as wt-eRF1 (Figure 4A, left
panel; data with mRNAs IV and V are similar and are not
shown). Cross-linking within the fragment 373–422 is
excluded based on analogous results with eRF1 mutants
carrying single substitutions of amino acids for Met in this
region (data not shown). To distinguish between the re-
maining candidate fragments 2–34 and 330–372, we con-
ducted cleavage of cross-linked peptide with various
proteolytic agents with subsequent analysis of the result-
ing products by Tris–tricine SDS–PAGE. Identiﬁcation of
short oligopeptides cross-linked to each mRNA analog
was based on comparison of relative positions of the
bands obtained with the respective proteolytic agents
with the map of eRF1 cleavage. The treatment of
cross-linked oligopeptide with an agent should result in
the changes of the respective SDS–PAGE pattern if the
oligopeptide contains site(s) for cleavage with this agent;
moreover, faster migrating band corresponds to shorter
oligopeptide cross-linked to the mRNA analog. So, we
treated bands b excised from the gels with endoprotease
ArgC, which has cleavage sites in fragment 2–34 but not in
fragment 330–372 (except for Arg330). With all mRNAs
III–V, the product corresponding to band b is sensitive to
ArgC implying that the cross-links are in positions 2–34
(Figure 6A, compare lanes 1 and 3).
To reﬁne the cross-link positions within the 2–34
fragment, the products corresponding to bands b were
cleaved with hydroxylamine, endoprotease ArgC or endo-
protease GluC (Figure 6, lanes 2–4). Treatment with
hydroxylamine causes slight but visible shift of bands b
indicating that the hydrolysis shortens the oligopeptide
slightly and therefore excludes cross-link in positions
31–34 (Figure 6, lanes 2). In all cases, the products result-
ing from treatment with ArgC (lanes 3, bands c) migrate
much more slowly than the fragment after the GluC
Figure 3. Mapping of cross-linking site(s) in human eRF1. (A) Autoradiogram. SDS–PAGE analysis of the fragments resulting from the
CNBr-induced cleavage of eRF1 cross-linked to end-labeled mRNA analogs. Lane numbers correspond to the numbers of mRNA analogs
(Figure 1). Positions of bands corresponding to molecular mass markers are given on the left. (B) Schematic representation of the CNBr-induced
cleavage sites of human eRF1 (437aa long), calculated masses of the fragments in kilo daltons are indicated above the diagram. The fragment
corresponding to band a is highlighted in black; candidate fragments for band b are presented in gray.
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that ArgC produces the cross-linked 11–28 fragment since
only in this case the cross-linked fragment obtained with
ArgC should be larger than any labeled fragment resulting
from GluC treatment (Figure 6B, lanes 3 and 4). To
identify more precisely positions of the cross-links within
fragment 11–28, we excised bands corresponding to
labeled products of bands b digested with GluC (namely,
bands d), and treated them with hydroxylamine, or pepsin
or endoprotease AspN (Figure 6A, lanes 5–7 and Figure
6C). Among three possible fragments resulting after GluC
treatment only the 26–34 fragment contains a site for
cleavage with hydroxylamine (Figure 6B, lane 4, and
Figure 6C, lane 5). Evidently, the product corresponding
to band d (Figure 6A, lanes 4) is sensitive to
hydroxylamine treatment, which leads to the formation
of a faster migrating product, band e, with all mRNAs
(Figure 6A, lanes 5). Consequently, bands d correspond
to the cross-linked 26–34 fragment. This identiﬁcation is
conﬁrmed by the results presented in Figure 6C (lanes 6
and 7) showing that the product corresponding to band d
is insensitive both to pepsin and to endoprotease AspN.
Indeed, of three candidate fragments that can correspond
to bands d (aa 2–13, 14–25 or 26–34) only the 26–34
fragment does not contain cleavage sites for AspN and
pepsin. Thus, the sites of mRNAs III–V cross-links are
mapped to fragment 26–28.
Data on cross-linking of mRNA analogs to eRF1 are
summarized in Table 1. It is clear that modiﬁed adenosines
in the second and third positions of a stop codon
Figure 4. Mapping of the cross-linking sites within the region 52–195 using double eRF1 mutants. (A) Autoradiograms. Patterns of CNBr-induced
cleavage fragments are obtained with two sets of double mutants (each set on a separate panel) cross-linked to mRNA analogs. Band a is marked by
analogy with Figure 3. The expected molecular masses (kDa) of the labeled products resulting from the CNBr-induced cleavage positions are given
on the sides of the panels (molecular masses of the cross-linked mRNA analogs were subtracted). (B) Schematic representations of the cleavage
sites together with calculated molecular masses (kDa) of the fragments resulting from the CNBr-induced cleavage. Cross-linked fragments are
presented as gray.
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cross-link becomes minor when the same nucleotide is in
the fourth position of the termination tetraplet where it
cross-reacts mainly with the 26–28 fragment. The latter
site is practically the only one when the cross-linker is at
the 30-phosphate of the UAA stop codon. Cross-linking to
this site is strongly reduced if the same group is at the
30-phosphate of the UAAA tetraplet, which cross-links
more strongly to the NIKS region.
A model for positioning of the UAA stop codon with
respect to eRF1 in the termination complex
In a previous study (24), we described two alternative
models of the eRF1 structure in the 80S termination
complex obtained by molecular modeling based on the
crystal structure of eRF1 and the available structural
and functional information related to positioning of
eRF1 toward the P-site-bound tRNA and the stop
codon in the ribosome. Brieﬂy, the structure of eRF1
was initially altered to ﬁt optimally to the ribosomal
A-site cavity. In particular, Y-shaped form of the eRF1
was transformed into a structure with a distance
between the NIKS and GGQ motifs close to the
distance between the anticodon triplet and the CCA-end
of tRNA. Then this eRF1 structure was docked at the
A-site-bound stop codon using the ribosomal structure
1JGO and the following constraints: CCA-end of the
P-site-bound tRNA should be located very close to the
GGQ tripeptide of eRF1, and NIKS motif should
neighbor the ﬁrst uridine of stop codon. One of two
obtained models [referred as M1 model in (24)] has been
chosen as ﬁtting well to the cross-linking data. In this
model, the mRNA passes through the cavity at the
surface of the N domain in a vicinity of the contact
between the N and C domains of eRF1, which adopts
an L-shape tRNA-like conformation. The distance
between the NIKS loop and the GGQ triplet is equal to
76A ˚ , and the distance between the stop codon and
the GGQ triplet is equal to 74A ˚ (exactly as between the
anticodon triplet and 30-terminal A in tRNA). In the
present study, the model was somewhat updated, in par-
ticular, to bring the GGQ tripeptide of eRF1 in closer
proximity to the CCA terminus of the P-site-bound
tRNA at the peptidyl transferase center of the ribosome
(Figure 7). In this reﬁned model, the surroundings of the
CCA terminus of the P-site-bound tRNA and the eRF1
nanopeptide HGRGGQSAL correspond to the RF1 
tRNA ribosome complex (accession code 2B64) with an
accuracy of 1A ˚ . Here, we have used this model to identify
the eRF1 amino acid residues that neighbor perﬂuoroph-
enyl azides at the UAAA termination tetraplet of mRNA
analogs in the 80S termination complexes (Table 2).
Figure 5. Mapping of the cross-linking site corresponding to fragment a within the 60–73 region using eRF1 mutants. (A) Patterns of CNBr-induced
cleavage fragments obtained with eRF1 mutants cross-linked to mRNA analogs. Bands a and b are marked by analogy with Figure 3. (B) Schematic
representation of the cleavage sites. Cross-linked fragments are highlighted in black.
7140 Nucleic Acids Research, 2011,Vol.39, No. 16It is noteworthy that in our model stop codon guanines
are proximal to a fragment of the C domain of the eRF1
centered around aa 360, which is not expected from the
X-ray structure of free eRF1 (18). But our model of
the eRF1 structure in the 80S termination complex ﬁts
the nuclear magnetic resonance (NMR) data demons-
trating that the C domain (minidomain 329–372) is
located proximately to the N domain of human eRF1
(42), which may be considered as an additional validation
of the model.
Figure 6. Mapping of the cross-linking site corresponding to fragment b within the 2–34 region. (A) Patterns of speciﬁc cleavage of the labeled
product corresponding to band b (Figure 3) with hydroxylamine (lane 2) and endoproteases ArgC (lane 3) and GluC (lane 4). Lanes 5–7 correspond
to treatment with hydroxylamine, endoprotease AspN or pepsin, respectively, of the labeled product d obtained as result of digestion of fragment b
with endoprotease GluC (lane 4). The panels represent separate electrophoregrams that are artiﬁcially aligned to bring all the bands b at the same
apparent migration positions. (B) Schematic representation of the CNBr-induced cleavage sites of human eRF1 and digestion of the 2–34 fragment
with hydroxylamine and endoproteases ArgC and GluC. Fragments containing the cross-link are marked in gray. (C) Schematic representation of the
cleavages of oligopeptides 2–13, 14–25 and 26–34 (shown with dotted vertical lines) in the 2–34 fragment with hydroxylamine, endoprotease AspN or
pepsin.
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The use of short mRNA analogs bearing perﬂuorophenyl
azide cross-linker at deﬁnite locations provides correct in-
formation on the immediate neighborhood of particular
mRNA nucleotides in the eukaryotic ribosomal com-
plexes. This conclusion is based on the comparison of
the data on 18S rRNA nucleotides proximal to various
mRNA positions obtained with these mRNA analogs
(40,41) and with longer synthetic mRNAs bearing 4-thiou-
ridine, a ‘zero-length’ cross-linker (24,43). Application
of both types of mRNA analogs led to identiﬁcation of
very similar sets of 18S rRNA nucleotides neighboring
mRNA in the 80S ribosomal complexes, despite different
natures of the cross-linkers used and various ways of the
formation of complexes. Locations of these 18S rRNA
nucleotides in the conserved core of the small subunit
rRNA secondary structure almost exactly corresponded
to the locations of 16S rRNA nucleotides contacting the
respective mRNA positions in the eubacterial 70S riboso-
mal complex (40,41), whose atomic structure is well known
from X-ray crystallographic data. Thus, cross-links of
perﬂuorophenyl azide-modiﬁed mRNA analogs to 18S
rRNA actually reﬂected immediate neighborhood of the
derivatized mRNA nucleotides in the eukaryotic riboso-
mal complexes, and needlessly to consider any of these
cross-links as false ones. All these justify consideration
of eRF1 peptides cross-linked to the mentioned mRNA
analogs as actual nearest neighbors of the derivatized stop
codon nucleotides in the 80S termination complexes.
The cross-linking results presented here indicate that
adenines in the second and third positions of the UAA
stop codon neighbor various parts of the region 125–131
containing the conserved YxCxxxF motif of human eRF1
(Table 1). Numerous data reported earlier indicate the
involvement of this region in recognition and discrimin-
ation of stop codon purines (19,23,25,26,27). Amino acids
of the YxCxxxF region of eRF1 have been found among
the targets for cross-linking of mRNA analogs bearing a
perﬂuorophenyl azide at the guanines in the UGA/UAG
stop codons (24). These data together with the results of
the present study show that amino acids of the YxCxxxF
region neighbor purines of any stop codon in the 80S ter-
mination complex and imply that involvement of this
region in recognition and/or discrimination of stop
codon purines is most probably based on their direct inter-
actions with YxCxxxF.
In this study, a novel site of cross-linking of mRNA
analogs to eRF1, 26-AAR-28, is reported (Table 1).
Figure 7. A model of positional relationship of mRNA, the
P-site-bound tRNA
Phe and the A-site-bound eRF1 in the 80S ribosomal
termination complex. (A) General view. Phosphate backbone of the
mRNA is presented as khaki tube; the P-site-bound tRNA
Phe is given
as dark blue tube; eRF1 is shown as ribbon (N domain is red, M
domain is green and C domain is green-blue). (B) Zoomed detailed
view of the part of the complex comprising the N domain of eRF1
and mRNA presented in the same way as in the general view. The
NIKS region, the GT dipeptide in positions 31 and 32 of eRF1 and
Arg28 are shown in the stick models (Arg28 is circled), YxCxxxF
region (positions 121–131) is marked as wide ribbon; eRF1 helices a2
and a3 are indicated. Nucleotides of the A-site-bound stop codon (nu-
cleotides in positions+4,+5 and+6 with respect to the ﬁrst nucleotide
of the P-site-bound codon) are shown in the stick models surrounded
by a pink area. Arrows indicate suggested directions of movements of
the N domain fragments.
Table 1. Cross-linking sites of mRNA analogs on human eRF1
mRNA
analog
(Figure 1A)
Position
of the
modiﬁed
nucleotide
b
and site of
the cross-linker
(shown in
brackets)
Distribution of cross-links
between fragments in the
N-domain of eRF1
a
Fragment ‘a’
(52–195)
Fragment ‘b’
(2–34)
I +5 (A) 127–132 (100%) No cross-links
II +6 (A) 121–124,
125–132 (100%)
No cross-links
III +7 (A) 121–124 (10%) 26–28 (90%)
IV +6 (p) Not identiﬁed 26–28 (>95%)
V +7 (p) 67–73 (25%) 26–28 (75%)
aQuantiﬁed data from Figure 3A in percent of the total amount of
cross-linked mRNA analog; relative error is  10%.
bWith respect to the 50-terminal nucleotide of the mRNA analog
(namely, to the ﬁrst nucleotide of the UUC triplet targeted to the P
site).
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organisms the eRF1 position 28 (here and hereafter
the human eRF1 numbering is used) is occupied by
arginine or lysine (44). Cross-linking of mRNA analogs
derivatized at the 30-phosphates to the 26-AAR-28 region
(Table 1) indicates close proximity of this fragment to
phosphates on the 30-side of the UAAA tetraplet. These
results provide the ﬁrst direct experimental data on pos-
itioning of the stop signal ribose-phosphate backbone
with respect to eRF1 in the 80S termination complex. It
is reasonable to suggest that the positively charged side
chain of arginine/lysine in eRF1 position 28 interacts
with the negatively charged phosphates 30 of adenosines
in the 3rd and 4th positions of the termination tetraplet.
Clearly, this interaction cannot mediate discrimination
of stop codon purines, but it may contribute to the
energy required for the interaction of eRF1 with a stop
codon.
A comparison of the results of the present study with
data on cross-linking of eRF1 to perﬂuorophenyl
azide-derivatized guanines in stop signals of mRNA
analogs (24) reveals two essential differences. First, the
31-GTx-33 motif of eRF1 was the main target for cross-
linking with modiﬁed guanines of a stop signal (24), but
this is not the case for adenines bearing a similar cross-
linker (the current study). This provides an indication that
positioning of eRF1 toward adenines and guanines of a
stop signal in the 80S termination complex is different.
The second distinction concerns application of the
cross-linking results to data on molecular modeling of
the termination complex. Previously (24), a comparison
of the results on cross-linking of eRF1 to perﬂuorophenyl
azide-derivatized guanines in stop signals of mRNA
analogs with the data of molecular modeling led us to
propose the positioning of the stop codon toward eRF1
in the termination complex: only one out of two models
(referred as model M1) ﬁtted the cross-linking results.
These previous cross-linking results were re-examined
with the updated model, in which the GGQ tripeptide
of eRF1 is located closer to the CCA terminus of the
P-site-bound tRNA, and the same conclusions were
reached. In particular, Thr32 from the conserved
31-GTx-33 motif, the major target for cross-linking of
the guanine-derivatized mRNA analogs (including the
analog with a modiﬁed G followed the UAA codon),
was present in the set of amino acid residues of eRF1
proximal to stop codon guanines (Table 2). However, in
the present study, using the same approach and mRNA
analogs bearing a similar cross-linker in the UAAA stop
signal, most of the cross-links are not compatible with
model M1. No cross-linking of derivatized adenines of
UAAA to the eRF1 positions around 63 and/or 65 in
the 61-NIKS-64 region is detected (Table 1), and, vice
versa, the observed cross-links of adenines in the second,
third and fourth stop signal positions to YxCxxxF region
(Table 1) are not expected from molecular modeling
(Table 2). Only cross-link of the 30-phosphate of the
UAAA tetraplet to Arg28 is anticipated from the model
(Table 2). This disagreement can be easily overcome if we
suggest that the N domain of eRF1 undergoes a conform-
ational rearrangements leading to a certain displacement
of its helices a2 and a3 (Figure 7B, thick dark blue arrows)
and of the GT dipeptide (Figure 7B, thick cyan arrow)
in opposite directions out of the central axis of the N
domain, leaving the arrangements of the Arg28 and
YxCxxxF region almost unchanged. These rearrange-
ments allowing the mRNA bases to be placed more
deeply in the binding pocket can explain the differences
in the eRF1 cross-linking patterns of derivatized stop
signal adenines and guanines. In particular, stop signal
guanines are recognized by eRF1 in a conformation cor-
responding to the M1 model (24), whereas recognition
of adenines requires eRF1 conformational alterations
involving changes of mRNA positioning with respect to
the 31-GT-32 dipeptide and helices a2 and a3 that occur
easily. The conformation that is preferable for recogni-
tion of adenines can be referred as a ‘modiﬁed pocket
conformation’. Deeper dipping of adenines into the
eRF1 binding pocket during stop signal recognition may
relate to the more hydrophobic nature of adenines as
compared to guanines. The modes of purine recognition
of stop signals suggested here might provide mechanisms
Table 2. Mutual positioning of cross-linkers at stop codon nucleotides and amino acid residues of eRF1 in the ribosomal
termination complex revealed from the molecular modeling
mRNA analog Position of the cross-linker site
(shown in brackets) with respect
to the ﬁrst nucleotide of the
P-site-bound UUC codon
Amino acid residues of eRF1 neighboring
N3 atoms of the cross-linker azide groups
a
UUC UA*A AAA +5 (A) R65, V66
UUC UAA* AAA +6 (A) K63-V66
UUC UAA A*AA +7 (A) R65, E365
UUC UAAp* +6 (30 phosphate) E104, T362-E367
UUC UAAAp* +7 (30 phosphate) R28, R29, R65, V101-E103, N129
bUUC UG*A AAA +5 (G) G31–T32, K63, C127, L312–E324, K354–K360
bUUC UAG* AAA +6 (G) G32–S33, N67–V71, Y125, K354–D359, E370
bUUC UAA G*AA +7 (G) G31–T32, N67–V71, Y125–K130, K360–H366
aTo ﬁnd these amino acid residues, the cross-linkers were added to the respective nucleotides of the mRNA in the models;
neighborhood in a 10-A ˚ range was taken into account.
bmRNA analogs derivatized at the guanines used in our previous work (24).
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contrast to eubacterial class 1 RFs.
The dipeptide GT in positions 31–32 of eRF1 is abso-
lutely conserved in eRF1 and its crucial role in stop codon
recognition together with the NIKS and YxCxxxF motifs
was predicted (44) and thereafter conﬁrmed experimental-
ly by site-directed mutagenesis (19). Thus, mutation
Thr32Ala led to much higher readthrough at both UAA
and UAG versus UGA stop codons indicating the import-
ance of this position for the recognition of A in the second
stop codon position (19); replacement of the asparagine
residue, immediately preceding the GT dipeptide, for His
in eRF1 resulted in a reduction of readthrough efﬁciency
with all three stop codons (28). Recently, it has been
shown that double substitutions of the non-charged
glycine and threonine of the GT dipeptide by the polar
and positively charged lysine and arginine in Euplotes
eRF1b lead to increased readthrough with all three stop
codons, conﬁrming the importance of this dipeptide for
stop codon recognition (30). It was suggested that
hydrogen bonds between Thr32 and Asn67 and between
Ser33 and Ser70, together with the sizes and hydrophobi-
city of Gly31 and Thr32, help to maintain a stable size and
orientation of binding pockets for stop codon bases.
Cross-linking data make it possible to consider that the
GT dipeptide is involved in binding of the stop signal
adenine and guanine in different ways. In particular,
eRF1 recognizes guanines in a conformation correspond-
ing to model M1 (24) where the GT dipeptide is located
close to the guanine and probably directly interacts with it.
On the contrary, to recognize adenines, eRF1 changes the
conformation of its N domain to adopt a ‘modiﬁed pocket
conformation’ so that the GT dipeptide does not interact
with the heterocyclic bases of the stop codon, although it
remains essential for the maintenance of the local con-
formation of the N domain suitable for binding of
adenines.
There is an additional eRF1 region, aa 70 and 71,
implicated in binding/discriminating purines in stop
codons. First, the eRF1 mutant Val71Met has been
reported to tend toward UAA unipotency (19). This
mutation might alter the structure of eRF1 to ﬁx it in a
‘modiﬁed pocket conformation’ preferable for recognition
of adenines and complicate the transition to the initial M1
structure that is required for interaction with guanines in
stop signals. The importance of a region around position
71 of eRF1 to discriminate purines in stop codons is also
followed from recent data demonstrating that the single
substitution Ala70Ser in eRF1 of Euplotes changes the
speciﬁcity of the factor from the bipotent UAR speciﬁcity
to the omnipotent one (29). However, the mechanism
whereby this eRF1 region is involved in purine discrimin-
ation in stop codons remains unknown. In the X-ray
structure of eRF1 complexed with eRF3 (19), Val71 is
located close to the bound ATP that is believed to
mimic a stop codon. On the other hand, cross-linking
data presented earlier (24) and in the current study show
that none of the mRNA analogs derivatized at the purine
bases of stop codons cross-links to the region surrounding
Ser70. The absence of the cross-links itself does not neces-
sarily mean that stop signal purines are not in close
proximity to this region since suitable targets for the
cross-linker might be lacking. However, probably this
suggestion is not applicable to this region because we
do observe cross-link in the fragment 67–73 with the
mRNA V derivatized at the UAAA 30-terminal phosphate
(Table 1). Therefore, based on the cross-linking data, we
suggest that the 70–71 region of eRF1 participates in the
interactions maintaining particular N domain conform-
ations responsible for the discrimination of purines in
stop codons rather than directly interacts with these
purines.
Thus, the data on cross-linking of eRF1 to mRNA
analogs derivatized at the guanines of stop signals (24)
and at the adenines of the UAAA tetraplet (this study)
revealed different positioning of these nucleotides with
respect to eRF1 in the 80S termination complexes. The
application of the cross-linking results to the structures
of eRF1 bound to the ribosome obtained by molecular
modeling showed that peptide neighborhoods of guanines
and adenines of stop signals are compatible with two al-
ternative conformations of the N domain of eRF1 in the
80S termination complex. The key difference between
these conformations of the N domain concerns the pos-
itioning of the stop signal purines with respect to the uni-
versally conserved dipeptide GT (positions 31–32) in eRF1
that neighbors or even interacts with guanines but is
oriented more distantly from adenines. The capability of
the ribosome-bound eRF1 to adopt alternative conform-
ations to recognize adenines and guanines without sub-
stantial consumption of energy could be essential for
recognition of all stop signals by the same class 1 termin-
ation factor in eukaryotes. The data obtained give a new
insight into the mechanism of stop signal decoding that re-
mains largely unknown due to the lack of cryo-EM
and X-ray crystallographic data on 80S termination
complexes.
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